Mannose coated selenium nanoparticles normalize intestinal homeostasis in mice and mitigate colitis by inhibiting NF-κB activation and enhancing glutathione peroxidase expression DOI Creative Commons
Hui Yang, Zhiyao Wang,

Lixin Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 10, 2024

Impaired intestinal homeostasis is a major pathological feature of inflammatory bowel diseases (IBD). Mannose and selenium (Se) both demonstrate potential anti-inflammatory anti-oxidative properties. However, most lectin receptors bind free monosaccharide ligands with relatively low affinity Se species induce side effects beyond very narrow range dosage. This has contributed to poorly explored therapies for IBD that combine mannose target epithelial cells (IECs) normalization gut homeostasis. Herein, facile safe strategy ulcerative colitis (UC) treatment was developed using optimized, mannose-functionalized nanoparticles (M-SeNPs) encapsulated within colon-targeted hydrogel delivery system containing alginate (SA) chitosan (CS). biocompatible nanosystem efficiently taken up by IECs led increased expression Se-dependent glutathione peroxidases (GPXs), thereby modulating IECs' immune response. Using mouse model DSS-induced colitis, (CS/SA)-embedding M-SeNPs (C/S-MSe) were found mitigate oxidative stress inflammation through the inhibition NF-kB pathway in colon. stabilized mucosal ameliorated colitis-related symptoms, providing new approach IBD.

Language: Английский

Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy DOI Creative Commons
Cui Liu, Xiangji Yan, Yujie Zhang

et al.

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: April 29, 2022

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by diffuse inflammation of the colonic mucosa and a relapsing remitting course. The current therapeutics are only modestly effective carry risks for unacceptable adverse events, thus more approaches to treat UC clinically needed.For this purpose, turmeric-derived nanoparticles with specific population (TDNPs 2) were characterized, their targeting ability therapeutic effects against investigated systematically. hydrodynamic size TDNPs 2 was around 178 nm, zeta potential negative (- 21.7 mV). Mass spectrometry identified containing high levels lipids proteins. Notably, curcumin, bioactive constituent turmeric, evidenced in 2. In lipopolysaccharide (LPS)-induced acute inflammation, showed excellent anti-inflammatory antioxidant properties. mice models, we demonstrated that orally administrated could ameliorate accelerate resolution via regulating expression pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, gene, HO-1. Results obtained from transgenic NF-κB-RE-Luc indicated 2-mediated inactivation NF-κB pathway might partially contribute protective effect these particles colitis.Our results suggest edible turmeric represent novel, natural colon-targeting may prevent promote wound repair while outperforming artificial terms low toxicity ease large-scale production.

Language: Английский

Citations

144
Multifunctional nanoparticle-mediated combining therapy for human diseases DOI Creative Commons
Xiaotong Li,

Xiuju Peng,

Makhloufi Zoulikha

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Jan. 1, 2024

Abstract Combining existing drug therapy is essential in developing new therapeutic agents disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established treating extensive human diseases. Attributed to synergistic effects by targeting various pathways advantages, such as reduced administration dose, decreased toxicity, alleviated resistance, combinatorial treatment now being pursued delivering combat major clinical illnesses, cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders neurodegenerative Combinatorial involves combining or co-delivering two more for a specific disease. Nanoparticle (NP)-mediated delivery systems, i.e., liposomal NPs, polymeric NPs nanocrystals, are great interest wide range due targeted delivery, extended release, higher stability avoid rapid clearance at infected areas. This review summarizes targets diseases, clinically approved combinations the development multifunctional emphasizes strategies based on severe Ultimately, we discuss challenging NP-codelivery translation provide potential approaches address limitations. offers comprehensive overview recent cutting-edge NP-mediated combination

Language: Английский

Citations

130
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis DOI Creative Commons

Caifang Gao,

Yangyang Zhou, Zhejie Chen

et al.

Theranostics, Journal Year: 2022, Volume and Issue: 12(12), P. 5596 - 5614

Published: Jan. 1, 2022

Rationale: Ulcerative colitis (UC), a typical kind of inflammatory bowel disease (IBD), is an idiopathic chronic intestinal inflammation.Conventional therapeutic strategies mainly focus on the rebalance pro-inflammation and anti-inflammation cytokines, whereas targeting damaged barriers, imbalanced microbiota dysregulated mucosal immune responses in UC remain big challenge.The objective this study was to develop turmeric-derived nanovesicles (TNVs) for alleviation explore underlying mechanisms.Methods: TNVs were isolated purified through differential centrifugation.The targeted ability evaluated dextran sulfate sodium (DSS)-induced mouse model by IVIS imaging system.The efficacy studied lipopolysaccharide (LPS)-induced macrophages DSS-induced acute colitic model.In addition, influence investigated via 16S rRNA microbiome sequence condition macrophage polarization after treatment analyzed flow cytometry.Results: characterized as nano-size spheroids.The experiment indicated that orally administrated could accumulate inflamed colon sites exhibited superior anti-inflammatory activity both vitro vivo.The sequencing suggested important role regulation gut microbiota.Further, promote transformation M1 phenotype M2 restore epithelium barrier exert anti-colitis efficacy.Conclusion: Collectively, oral administration excellent restoring barrier, regulating reshaping phenotype.This sheds light application natural exosome-like UC.

Language: Английский

Citations

120
Oral colon-targeted mucoadhesive micelles with enzyme-responsive controlled release of curcumin for ulcerative colitis therapy DOI
Chen Zhang, Jiaxin Li, Meng Xiao

et al.

Chinese Chemical Letters, Journal Year: 2022, Volume and Issue: 33(11), P. 4924 - 4929

Published: April 2, 2022

Language: Английский

Citations

114
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer DOI Creative Commons
Ruize Qu, Yi Zhang,

Yanpeng Ma

et al.

Advanced Science, Journal Year: 2023, Volume and Issue: 10(23)

Published: June 1, 2023

Colorectal cancer (CRC) is the most common of digestive system with high mortality and morbidity rates. Gut microbiota found in intestines, especially colorectum, has structured crosstalk interactions host that affect several physiological processes. The gut include CRC-promoting bacterial species, such as Fusobacterium nucleatum, Escherichia coli, Bacteroides fragilis, CRC-protecting Clostridium butyricum, Streptococcus thermophilus, Lacticaseibacillus paracasei, which along other microorganisms, viruses fungi, play critical roles development CRC. Different features are identified patients early-onset CRC, combined different patterns between fecal intratumoral microbiota. may be beneficial diagnosis treatment CRC; some bacteria serve biomarkers while others regulators chemotherapy immunotherapy. Furthermore, metabolites produced by essential CRC cells. Harmful primary bile acids short-chain fatty acids, whereas others, including ursodeoxycholic acid butyrate, impede tumor progression. This review focuses on its metabolites, their potential development, diagnosis,

Language: Английский

Citations

106
Immunomodulatory biomaterials and their application in therapies for chronic inflammation-related diseases DOI

Jayachandra Reddy Nakkala,

Ziming Li,

Wajiha Ahmad

et al.

Acta Biomaterialia, Journal Year: 2021, Volume and Issue: 123, P. 1 - 30

Published: Jan. 21, 2021

Language: Английский

Citations

104
Mucoadhesive carriers for oral drug delivery DOI Creative Commons
Raj Kumar, Tamanna Islam, Md Nurunnabi

et al.

Journal of Controlled Release, Journal Year: 2022, Volume and Issue: 351, P. 504 - 559

Published: Sept. 30, 2022

Language: Английский

Citations

94
Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer DOI Creative Commons
Juanjuan Li, Yuqing Hu, Bing Hu

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Oct. 21, 2022

Abstract Diabetic wound is one of the most intractable chronic wounds that prone to bacterial infection. Hypoxia an important feature in its microenvironment. However, it challenging for antimicrobial therapy directly apply existing hypoxia-responsive drug delivery systems due active targeting deficiency and biofilm obstacle. Herein, we customizes a carrier, lactose-modified azocalix[4]arene (LacAC4A) with ability actively target inhibit biofilm. By loading ciprofloxacin (Cip), resultant supramolecular nanoformulation Cip@LacAC4A demonstrates enhanced antibacterial efficacy resulting from both increased accumulation controlled release at site When applied on diabetic together multidrug-resistant Pseudomonas aeruginosa infection vivo, induces definitely less inflammatory infiltration than free Cip, which translates into high healing performance. Importantly, such design principle provides direction developing systems.

Language: Английский

Citations

93
New and Emerging Treatments for Inflammatory Bowel Disease DOI Open Access
Masaaki Higashiyama, Ryota Hokari

Digestion, Journal Year: 2022, Volume and Issue: 104(1), P. 74 - 81

Published: Nov. 10, 2022

Background: The specific etiopathogenesis of inflammatory bowel disease (IBD) is still unknown. Although the conventional anti-inflammatory or immunomodulatory drugs relatively nonspecific to pathogenesis have been quite useful in many cases, elucidating has gradually facilitated developments disease-specific therapies for refractory cases last 2 decades. Summary: With a greater understanding multiple overactive signaling pathways gut mucosal immune response and enhanced leukocyte trafficking, several biological agents small molecule following first novel biologic, anti-tumor necrosis factor α (anti-TNFα), developed against modes action including adhesion molecules, sphingosine-1-phospate receptors, cytokines (IL-12/23, TL1A, IL-36), Janus kinase (JAK), phosphodiesterase. preceding dramatically changed IBD treatment strategy, patients require alternative due failure side effects. Newer treatments are now expected be provided better efficacy with an improved adverse event profile. In addition, translational studies highlighted new therapeutic concepts’ potential, modulation host-microbiome interactions, stem therapy perianal fistula, regulation fibrosis, gut-brain axis, control previously less targeted cells (B innate lymphoid cells). This paper comprehensively reviewed not only latest already shortly available but also emerging promising that will hopefully established future IBD. Key Messages: Many kinds available, perspectives emerge future.

Language: Английский

Citations

71
Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems DOI

Hicheme Hadji,

Kawthar Bouchemal

Advanced Drug Delivery Reviews, Journal Year: 2022, Volume and Issue: 181, P. 114101 - 114101

Published: Jan. 6, 2022

Language: Английский

Citations

70